Chlorthalidone: Mechanisms of action and effect on cardiovascular events

Current Hypertension Reports

Volumn 15, Issue 5, 2013, Pages 514-521

  Roush, George C ^a   Buddharaju, Venkata ^a   Ernst, Michael E ^b   Holford, Theodore R ^c  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

Blood pressure; BP; Carbonic anhydrases; Chlorthalidone; CTDN; Endothelium; Hydrochlorothiazide; Hypertension complications; Thiazides therapeutic use; Vascular drug effects

Indexed keywords

AMLODIPINE; CARBONATE DEHYDRATASE; CHLORTALIDONE; GLUCOSE; HYDROCHLOROTHIAZIDE; LISINOPRIL; POTASSIUM; URIC ACID;

ANTIHYPERTENSIVE ACTIVITY; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; DRUG DISTRIBUTION; DRUG HALF LIFE; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; PLEIOTROPY; POTASSIUM BLOOD LEVEL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHLORTHALIDONE; HUMANS; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 84893688004     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0372-1     Document Type: Article

References (57)

1. Riess W, Dubach UC, Burckhardt D, Theobald W, Vuillard P, Zmmerli M. Pharmacokinetic studies with chlorthalidone (Hygroton) in man. Eur J Clin Pharmacol. 1977;12:375-82.
2. Collste P, Garle M, Rawlins MD, Sjogvist F. Interindividual differences in chlorthalidone concentration in plasma and red cells of man after single and multiple doses. Eur J Clin Pharmacol. 1976;9:319-25.
3. Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med. 2009;361:2153-64.
4. Bengtsson C, Johnsson G, Sannerstedt R, Werkö L. Effect of different doses of chlorthalidone on blood pressure, serum potassium, and serum urate. BMJ. 1975;1:197-9.
5. Neuvonen PJ, Pentikäinen PJ, Jounela AJ. Effect of diuretic, β-adrenoceptor blocking agent and their combination on elevated blood pressure and serum potassium: a cross-over study. Br J Clin Pharmacol. 1978;6:363-7.
6. Materson BJ, Oster JR, Michael UF, Bolton SM, Burton ZC, Stambaugh JE, et al. Dose response to chlorthalidone in patients with mild hypertension. Efficacy of a lower dose. Clin Pharmacol Ther. 1978;24(2):192-8.
7. Tweeddale MG, Ogilvie RI, Ruedy J. Antihypertensive and biochemical effects of chlorthalidone. Clin Pharmacol Ther. 1977;22(5 Pt 1):519-27.
8. Russell JG, Mayhew SR, Humphries IS. Chlorthalidone in mild hypertension-dose response relationship. Eur J Clin Pharmacol. 1981;20:407-11.
9. Morledge JH, Ettinger B, Aranda J, McBarron F, Barra P, Gorwit J, et al. Isolated systolic hypertension in the elderly. A placebocontrolled, dose-response evaluation of chlorthalidone. J Am Geriatr Soc. 1986;34:199-206.
10. Ernst ME, Goerdt CJ, Carter BL, Steffensmeier JJ, Phillips BB, Zimmerman MB, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352-8. This trial shows that CTDN is superior to HCTZ in lowering nighttime BP, -13.5 versus -6.4, respectively.
11. Ernst ME, Carter BL, Zheng S, Grimm Jr RH. Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am J Hypertens. 2010;23:440-6.
12. Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension. 2012;59:1104-9.
13. Bakris GL, Sica D, White WB, Cushman WC, Weber MA, Handley A, et al. Antihypertensive efficacy of hydrochlorothiazide versus chlorthalidone combined with azilsartan medoxomil. Am J Med 2012;125:1229.e1-1229.e10. This trial shows that CTDN lowers office and 24 h BP more than HCTZ with differences of -5.6 and -5.8, respectively.
14. Tarzi RC, Dustan HP, Frohlich ED. Long-term thiazide therapy in essential hypertension. Evidence for persistent alterations in plasma volume and renin activity. Circulation. 1970;41:709-17.
15. Wilson IM, Freis ED. Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effect of chlorothiazide. Circulation. 1959;20:1028-36.
16. Gifford Jr RW, Mattox VR, Orvis AL, Somes DA, Rosevear JW. Effect of thiazide diuretics on plasma volume, body electrolytes, and excretion of aldosterone in hypertension. Circulation. 1961;24:1197-205.
17. Roos JC, Boer P, Koomans HA, Sones DA, Rosevear JW. Haemodynamic and hormonal changes during acute and chronic diuretic treatment in essential hypertension. Eur J Clin Pharmacol. 1981;19:107-12.
18. Tobian L. Why do thiazide diuretics lower blood pressure in essential hypertension? Annu Rev Pharmacol. 1967;7:399-408.
19. Winer BM. The antihypertensive actions of benzothiadiazines. Circulation. 1961;23:211-8.
20. Hughes AD. How do thiazide and thiazide-like diuretics lower blood pressure? J Renin-Angiotensin-Aldosterone Syst. 2004;5:155-60.
21. Bagatin J, Pavlicevic I, Sardelic S, Pivac N, Rumboldt Z. Vascular effects of chlorthalidone in mild hypertensives. Int J Clin Pharmacol Res. 1995;15:201-8.
22. Puscas I, Coltau M, Baican M, Domuta G, Hecht A. Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25:271-9.
23. Temperini C, Cecchi A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: sulfonamide diuretics revisited-old leads for new applications? Org Biomol Chem. 2008;6:2499-506.
24. Kurtz TW. Chlorthalidone: don't call it "thiazide-like" anymore. Hypertension. 2010;56:335-7.
25. Calder JA, Schachter M, Sever PS. Potassium channel opening properties of thiazide diuretics in isolated guinea pig resistance arteries. J Cardiovasc Pharmacol. 1994;24:158-64.
26. Pickkers P, Garcha RS, Schachter M, Smits P, Hughes AD. Inhibition of carbonic anhydrase accounts for the direct vascular effects of hydrochlorothiazide. Hypertension. 1999;33:1043-8.
27. Aamand R, Dalsgaard T, Jensen FB, Simosen U, Roepstorff A, Fago A. Generation of nitric oxide from nitrite by carbonic anhydrase: a possible link between metabolic activity and vasodilation. Am J Physiol Heart Circ Physiol. 2009;297:H2068-74.
28. Yamanari H, Nakamura K, Miura D, Yamanari S, Ohe T. Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress. Clin Exp Hypertens. 2009;31(7):585-94.
29. Dell'Omo G, Penno G, Del Prato S, Pedrinelli R. Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome. J Cardiovasc Pharmacol Ther. 2005;10(4):265-72.
30. Woodman R, Brown C, Lockette W. Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis. Hypertension. 2010;56(3):463-70.
31. Vaitkevicius H, Turner I, Spalding A, Lockette W. Chloride increases adrenergic receptor-mediated platelet and vascular responses. Am J Hypertens. 2002;15(6):492-8.
32. Sato K, Dohi Y, Kojima M Takase H, Suzuki S, Ito S. Antioxidative effects of thiazide diuretics in refractory hypertensive patients. 2010;60(10):612-6.
33. McEniery CM, Wallace S, Mackenzie IS, McDonnell B, Yasmin, Newby DE. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension. 2006;48(4):602-8. Epub 2006 Aug. 28.
34. Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation. 2010;121(4):505-11.
35. Kwon BJ, Jang SW, Choi KY, Kim DB, Cho EJ, Ihm SH, et al. Comparison of the efficacy between hydrochlorothiazide and chlorthalidone on central aortic pressure when added on to candesartan in treatment-naïve patients of hypertension. Hypertens Res. 2013;36(1):79-84.
36. Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med. 1998;158(7):741-51.
37. Dorsch MP, Gillespie BW, Erickson SR, et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57:689-94. This head-to-head comparison of the 2 drugs in an observational cohort study shows a 21 % reduction in CVEs from CTDN versus HCTZ.
38. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000;35(5):1025-30.
39. Kostis JB, Lacy CR, Hall WD, Wilson AC, Borhani NO, Krieger SD, et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. The SHEP Study Group. Am J Cardiol. 1994;74(5):464-7.
40. Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, et al. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipidlowering treatment to prevent heart attack trial. Hypertension. 2012;59(5):926-33. This observational study concludes: "Thus, for most patients, concerns about potassium levels should not influence the clinician's decision about initiating hypertension treatment with low-moderate doses of thiazide diuretics (12.5-25. 0 mg of C [chlorthalidone]) ".
41. Shafi T, Appel LJ, Miller ER, Klag MJ, Parekh RS. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension. 2008;52:1022-9.
42. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166(20):2191-201.
43. Barzilay JI, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Black HR, et al. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcome. 2012;5(2):153-62.
44. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95(1):29-35.
45. Wright Jr JT, Probstfield JL, Cushman WC, Pressel SL, Cutler JA, Davis BR, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med. 2009;169(9):832-42.
46. Menon DV, Arbique D, Wang Z, Adams-Huet B, Auchus RJ, Vongpatanasin W. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab. 2009;94(4):1361.
47. Raheja P, Price A, Wang Z, Arbique D, Adams-Huet B, Auchus RJ, et al. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension. 2012;60(2):319-25.
48. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. Prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension. 1985;7:105-12.
49. Ofili EO, Cohen JD, St Vrain JA, Pearson A, Martin TJ, Uy ND, et al. Effect of treatment of isolated systolic hypertension on left ventricular mass. JAMA. 1998;279:778-80.
50. Ernst ME, Neaton JD, Grimm Jr RH, Collins G, Thomas W, Soliman EZ, et al. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the Multiple Risk Factor Intervention Trial. Hypertension. 2011;58:1001-7. CTDN reduces LVH in this observational study of the MRFIT trial.
51. Bacharova L, Estes H, Bang L, Rowlandson I, Schillaci G, Verdecchia P, et al. The first statement of the Working Group on Electrocardiographic Diagnosis of Left Ventricular Hypertrophy. J Electrocardiol. 2010;43:197-9.
52. Hsieh BP, Pham MX, Froelicher VF. Prognostic value of electrocardiographic criteria for left ventricular hypertrophy. Am Heart J. 2005;150:161-7.
53. Jain A, Tandri H, Dalal D, Chahal H, Soliman EZ, Prineas RJ, et al. Diagnostic and prognostic utility of electrocardiography for left ventricular hypertrophy defined by magnetic resonance imaging in relationship to ethnicity: the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2010;159:652-8.
54. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012;59(6):1110-7. This network meta-analysis finds that CTDN reduces CVEs by 21 % more than HCTZ.
55. Dhalla IA, Gomes T, Yao Z, Nagge J, Persaud N, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann Intern Med. 2013;158(6):447-55.
56. Roush GC, Holford TR, Guddati AK. Comment. Chlorthalidone versus hydrochlorothiazide. Ann Intern Med. 2013;158:920.
57. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.